Home › Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
 

Keywords :   


Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium

2014-12-10 14:30:00| Merck.com - Corporate News

Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data advanced san presented

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05BeautyHealth: Q1 2024 Financials
10.05Research Institute for Fragrance Materials to Promote Online Database on May 22
10.05Hairstory Promotes Dina Rosenbloom To Chief Executive Officer
10.05Net Sales Decrease 5% for The Clorox Company in Q3 2024
10.05Sunak says it'll take time for people to feel better
10.05Alabama second state to ban lab-grown meat
10.05Alabama second state to ban lab-grown meat
10.05Senators request more aggressive approach on HPAI countermeasures
More »